Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

1.16
-0.0100-0.85%
Post-market: 1.190.0300+2.59%18:59 EDT
Volume:46.43K
Turnover:54.21K
Market Cap:22.69M
PE:-1.97
High:1.19
Open:1.17
Low:1.14
Close:1.17
Loading ...

Lexaria Bioscience completes dosing for GLP-1 human pilot study #3

TIPRANKS
·
25 Nov 2024

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ACCESSWIRE
·
25 Nov 2024

Lexaria Bioscience Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Nov 2024

Lexaria Bioscience’s DehydraTECH Outshines in Diabetes Study

TIPRANKS
·
21 Nov 2024

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

ACCESSWIRE
·
20 Nov 2024

Lexaria Bioscience Corp expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
16 Nov 2024

Lexaria Bioscience Launches Innovative Drug Study

TIPRANKS
·
15 Nov 2024

Lexaria Bioscience signs contract for DehydraTECH GLP-1 biodistribution study

TIPRANKS
·
14 Nov 2024

Lexaria : Study Work Has Already Begun With Completion and Final Reporting Expected in May, 2025

THOMSON REUTERS
·
14 Nov 2024

Lexaria Signs Contract for New Dehydratech Glp-1 Biodistribution Study

THOMSON REUTERS
·
14 Nov 2024

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

ACCESSWIRE
·
14 Nov 2024

Lexaria Bioscience Advances GLP-1 Study

TIPRANKS
·
14 Nov 2024

Lexaria Bioscience Gets Ethics Board Approval to Begin Dosing in Phase 1b Diabetes, Weight Loss Study

MT Newswires Live
·
14 Nov 2024

Lexaria Bioscience receives HREC approval for Phase 1b DehydraTECH GLP-1 study

TIPRANKS
·
13 Nov 2024

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

ACCESSWIRE
·
13 Nov 2024

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

ACCESSWIRE
·
07 Nov 2024